JOP20190280A1 - مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية - Google Patents

مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Info

Publication number
JOP20190280A1
JOP20190280A1 JOP/2019/0280A JOP20190280A JOP20190280A1 JO P20190280 A1 JOP20190280 A1 JO P20190280A1 JO P20190280 A JOP20190280 A JO P20190280A JO P20190280 A1 JOP20190280 A1 JO P20190280A1
Authority
JO
Jordan
Prior art keywords
treating
patient
treating cholangiocarcinoma
fgfr2
fgfr2 inhibitors
Prior art date
Application number
JOP/2019/0280A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20190280A1 publication Critical patent/JOP20190280A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

تم الكشف فيما يلي عن طرق علاج سرطان الأوعية الصفراوية في مريض تتضمن: تقييم عينة بيولوجية من المريض من حيث وجود واحد أو أكثر من متطفرات FGFR شاملة على الأقل FGFR2 SNP C383R؛ وعلاج المريض بمثبط FGFR في حال تواجد واحد أو أكثر من متطفرات FGFR تشمل على الأقل FGFR2 SNP C383R في العينة.
JOP/2019/0280A 2017-06-02 2017-06-16 مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية JOP20190280A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP18171315 2018-05-08

Publications (1)

Publication Number Publication Date
JOP20190280A1 true JOP20190280A1 (ar) 2019-12-02

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0280A JOP20190280A1 (ar) 2017-06-02 2017-06-16 مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Country Status (16)

Country Link
US (2) US11707463B2 (ar)
EP (1) EP3634414A1 (ar)
JP (2) JP2020521794A (ar)
KR (1) KR20200010505A (ar)
CN (1) CN111050769A (ar)
AU (1) AU2018278271B2 (ar)
BR (1) BR112019025056A2 (ar)
CA (1) CA3064317A1 (ar)
IL (1) IL271058A (ar)
JO (1) JOP20190280A1 (ar)
MA (1) MA49248A (ar)
MX (1) MX2019014366A (ar)
MY (1) MY204203A (ar)
PH (1) PH12019502710A1 (ar)
UA (1) UA126478C2 (ar)
WO (1) WO2018220206A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020243273A2 (en) 2019-05-28 2020-12-03 Qed Therapeutics, Inc. Methods of treating cholangiocarcinoma
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途
JP2023512482A (ja) * 2020-01-17 2023-03-27 ベータ・ファーマ・インコーポレイテッド Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
CA2680046A1 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Methods of diagnosing, classifying and treating endometrial cancer and precancer
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
AU2018278271B2 (en) 2024-07-04
CN111050769A (zh) 2020-04-21
KR20200010505A (ko) 2020-01-30
PH12019502710A1 (en) 2020-06-08
EP3634414A1 (en) 2020-04-15
US20240016801A1 (en) 2024-01-18
US12350266B2 (en) 2025-07-08
CA3064317A1 (en) 2018-12-06
JP2020521794A (ja) 2020-07-27
AU2018278271A1 (en) 2019-12-05
WO2018220206A1 (en) 2018-12-06
MY204203A (en) 2024-08-15
US11707463B2 (en) 2023-07-25
JP2023113650A (ja) 2023-08-16
IL271058A (en) 2020-01-30
US20200138809A1 (en) 2020-05-07
BR112019025056A2 (pt) 2020-06-16
UA126478C2 (uk) 2022-10-12
MA49248A (fr) 2020-04-15
MX2019014366A (es) 2020-07-27

Similar Documents

Publication Publication Date Title
JOP20190280A1 (ar) مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
CY1125190T1 (el) Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα
CL2018001110A1 (es) Mutaciones de punto en cáncer resistente a inhibidor de trk y métodos relacionados con el mismo
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2018008166A (es) Sistemas y metodos para confirmar la activacion de indicadores biologicos.
AR100766A1 (es) Sistema de expresión génica
EP3693742A3 (en) Methods of detecting prostate cancer
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
FR3026194B1 (fr) Forme d'onde radar, procede de detection radar utilisant une telle onde, et radar mettant en oeuvre le procede
EA201992849A1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
EA202190962A2 (ru) Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
EA202190826A1 (ru) Лечение холангиокарциномы
BR112017017418A2 (pt) heterociclos bicíclicos como inibidores de fgfr
UA95580U (uk) Спосіб прогнозування зрощення перелому
UA95590U (uk) Спосіб прогнозування зрощення перелому
RU2015110486A (ru) Способ оценки результатов воздействия микроорганизмов на пролиферацию клеток в макроорганизме
BR112017010902A2 (pt) método para identificar a presença ou ausência de um ácido nucleico alvo em uma amostra biológica.
UA98477U (uk) Спосіб визначення маркера системного запалення шляхом оцінки макрофагальної реакції жирової тканини
UA95638U (uk) Спосіб прогнозування зрощення перелому